New drug trial offers hope for rare MELAS fatigue and brain fog
NCT ID NCT06402123
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests an experimental drug called zagociguat in 43 adults with MELAS, a rare genetic disease that causes strokes, fatigue, and thinking problems. Participants take either 15 mg, 30 mg, or a placebo daily for 12 weeks. The goal is to see if the drug reduces fatigue and improves memory and thinking, while checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akron Children's Hospital
Akron, Ohio, 44308, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Children's Hospital of Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Columbia University Irving Medical Center
New York, New York, 10027, United States
-
Fondazione Policlinico Universitario Agostino Gemelli
Roma, 00168, Italy
-
Ludwig-Maximilians-University of Munich
Munich, 80336, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
McMaster University Medical Center
Hamilton, Ontario, L8N 3Z5, Canada
-
Mount Sinai - Ichan School of Medicine
New York, New York, 10029, United States
-
Neurologic Institute Carlo Besta of Milan
Milan, 20133, Italy
-
Neuroscience Research Australia
Sydney, New South Wales, NSW 2031, Australia
-
Newcastle University
Newcastle upon Tyne, NE14LP, United Kingdom
-
Rare Disease Research
Atlanta, Georgia, 30329, United States
-
Royal Melbourne Hospital
Melbourne, Victoria, 3052, Australia
-
Shared Health/University of Manitoba
Winnipeg, Manitoba, R3A1R9, Canada
-
UC San Diego - Altman Clinical and Translational Research Institute
La Jolla, California, 92037, United States
-
UCL Queen Square Institute of Neurology
London, WC1N 3BG, United Kingdom
-
University Hospital Bonn
Bonn, 53127, Germany
-
University of Texas Medical School at Houston
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.